Juniper Pharmaceuticals’ (Nasdaq: JNP) core businesses include its CRINONE® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end, fee-for-service pharmaceutical development and clinical trials manufacturing to clients.
The Company has a successful history in developing pharmaceutical products, including Crinone® 8% (progesterone gel), which is commercially available in the United States and over 90 countries around the world.
We provide high end services including pharmaceutical development, clinical trial supply manufacturing, and analytical capabilities to clients, while also providing valuable intellectual property-related consultative services to our pharmaceutical industry customers.
Juniper is positioned for success with a highly experienced leadership team in combination with a solid balance sheet and strong cash flows to build our core business and create long term value.
Crinone® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.